NovoCure (NVCR) Q3 2024 earnings summary

Executive summary

• Net revenues reached $155.1 million in Q3 2024, up 22% year-over-year, driven by launches in France and improved U.S. approval rates, with 4,113 active patients on therapy, a 13% increase year-over-year.

• FDA approved and launched Optune Lua (LUNAR) for metastatic non-small cell lung cancer in the U.S., expanding the addressable market.

• CEO transition announced: Asaf Danziger retiring, Ashley Cordova promoted to CEO, Christoph Brackmann joining as CFO effective January 2025.

• Anticipated top-line data from PANOVA-3 phase 3 clinical trial in Q4 2024; PANOVA-4 phase 2 enrollment complete.

• FDA Breakthrough Device designation granted for TTFields therapy in brain metastases from NSCLC.

Financial highlights

• Net revenues: $155.1 million, up 22% year-over-year; U.S. contributed $98.3 million, Germany $17.0 million, France $15.2 million, Japan $8.6 million.

• Gross margin improved to 77% from 75% year-over-year, attributed to higher net revenue per patient and strong performance in France.

• Adjusted EBITDA was $1.7 million for Q3 2024, a significant improvement from $(29.1) million in Q3 2023.

• Net loss for the quarter was $30.6 million ($0.28 per share), narrowed from $49.5 million in Q3 2023.

• Cash, cash equivalents, and short-term investments totaled $959.9 million as of September 30, 2024.

Outlook and guidance

• Top-line data from the PANOVA-3 phase 3 pancreatic cancer trial expected in Q4 2024; additional trial data in 2026.

• LUNAR commercial launch in mNSCLC ongoing in the U.S., with plans for global expansion and reimbursement establishment; U.S. reimbursement for lung indication anticipated to take 1–2 years.

• Gross margin expected to face headwinds from next-generation arrays and lung indication launch, but to normalize within 6–8 quarters.

• Cash and investments expected to fund operations for at least the next 12 months.

• Anticipates increased operating expenses as the company prepares for expansion into new indications.